RA was well tolerated in the Phase I trial. Now MBX is planning a Phase II trial in post-bariatric hypoglycaemia patients.

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...

Explore how inhibiting myostatin can promote muscle mass in men, addressing sarcopenia, GLP-1 medication effects, and aging ...

New in vivo preclinical data announced today, demonstrate that icovamenib, in combination with semaglutide showed additional 11.5% body weight ...

Research showed that patients who lose weight on GLP-1 agonists frequently experience muscle mass loss. Obesity experts share ...

Weight loss tops many folks' list of New Year's resolutions, and lots of people are turning to cutting-edge weight-loss drugs ...

Intuitively, it would seem that GLP-1 use for obesity would reduce overall medical costs despite the increase in drug ...

Retatrutide, a synthetic peptide with unique properties, has recently gained attention for its multifunctional roles and the ...

The news was just the latest in a cavalcade of headlines about copycat glucagon-like peptide 1 (GLP-1) agonists. The blockbuster drugs used for weight loss and to treat diabetes are in such high ...

Antimicrobial peptides ... 1. Immunomodulatory host defense peptides affect a wide range of immune cells, including T-cells, B-cells, non-killer cells, macrophages, monocytes, CD4+ and CD8+ T cells.

This Viewpoint discusses factors associated with the prevalence of obesity worldwide and whether the novel glucagon-like peptide-1 receptor agonists (GLP-1) can help unlock a health systems response ...